DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0121152 A1 Jenkins Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0121152 A1 Jenkins Et Al US 20140121152A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0121152 A1 Jenkins et al. (43) Pub. Date: May 1, 2014 (54) ACTIVE AGENT PRODRUGS WITH Publication Classification HETEROCYCLIC LINKERS (51) Int. C. C07K5/06 (2006.01) (75) Inventors: Thomas E. Jenkins, Half Moon Bay, A638/05 (2006.01) CA (US); Craig O. Husfeld, San Mateo, A6II 45/06 (2006.01) CA (US) C07K5/08 (2006.01) A638/06 (2006.01) (73) Assignee: Signature Therapeutics, Inc., Palo Alto, (52) U.S. C. CA (US) CPC. C07K5/06 (2013.01); C07K5/08 (2013.01); A6 IK38/06 (2013.01); A61K 45/06 (2013.01); (21) Appl. No.: 14/000,594 A6 IK38/05 (2013.01) USPC 514/1.3: 530/331:546/44; 546/226,544/361 (22) PCT Fled: Mar. 8, 2012 (57) ABSTRACT (86) PCT NO.: PCT/US12/28367 The embodiments provide prodrug compounds of Formulae S371 (c)(1), I-XVII. The present disclosure also provides compositions, (2), (4) Date: Dec. 27, 2013 and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XVII that provides con trolled release of an active agent. Such compositions can Related U.S. Application Data optionally provide a trypsin inhibitor that interacts with the (60) Provisional application No. 61/451,019, filed on Mar. enzyme that mediates the controlled release of an active agent 9, 2011, provisional application No. 61/583,523, filed from the prodrug so as to attenuate enzymatic cleavage of the on Jan. 5, 2012. prodrug. Patent Application Publication May 1, 2014 Sheet 1 of 26 US 2014/O121152 A1 Figure 1 A. ---. x N srax °, w y . %. '. '. thiitor Patent Application Publication May 1, 2014 Sheet 2 of 26 US 2014/O121152 A1 Figure 2 38ts s S. SSS Srs Patent Application Publication May 1, 2014 Sheet 3 of 26 US 2014/O121152 A1 Figure 2 (continued) 3S 8. Patent Application Publication May 1, 2014 Sheet 4 of 26 US 2014/O121152 A1 Figure 3 Site, - &FES fi & s s H H Fiss SSS $s ELS&S ISS & PSE { R&FE: s & ........ : s al s E. & & & s s 8 s *:::SF:SESS $3. Lists RSSS 8:S E ; F S s I 8. ESSESSS SSSSSSSS: Patent Application Publication May 1, 2014 Sheet 5 of 26 US 2014/O121152 A1 Figure 4 -O OC from Oxycodone (28 umol/kg) -be OC from Compound KC-9 (31 umol/kg) - OC from Compound KC-11 (34 umol/kg) 1OO OC from Compound KC-12 (29 umol/kg) - OC from Compound KC-13 (29 umol/kg) -- OC from Compound KC-14 (29 umol/kg) -0. OC from Compound KC-15 (29 umol/kg) 10 -- OC from Compound KC-16 (29 umol/kg) - OC from Compound KC-17 (28 umol/kg) S o C g : 1 e x 9. O.1 O.O1 Time, hr Patent Application Publication May 1, 2014 Sheet 6 of 26 US 2014/O121152 A1 Figure 5A -A OC from Oxycodone (5.7 umol/kg) -0- OC from 20 mg OxyContin Tablet -e OC from Compound KC-12 (5.7 umol/kg) -H OC from Compound KC-13 (5.7umol/kg) -e OC from Compound KC-14 (5.7 umol/kg) OC from Compound KC-15 (5.7 umol/kg) as OC from Compound KC-16 (5.8 umol/kg) cHe OC from Compound KC-17 (5.8 umol/kg) - S 2 10 o o S 1 5 0.1 OO1 Time, hr Figure 5B 1000 -o- OC from Compound KC-17 (5.8 umol/kg) -A OC from Oxycodone (5.7umol/kg) -0- OC from 20 mg OxyContin Tablet -H OC from Compound KC-3 (5.7 umol/kg) E o O s O ce g 9. Time, hr Patent Application Publication May 1, 2014 Sheet 7 of 26 US 2014/O121152 A1 Figure 6A -o- OC from Compound KC-12 (6.5 pmol/kg) 1OO -H OC from Compound KC-12 (29 umol/kg) - 10 S d 5 1 O ce X 9. O.1 0.01 O 6 12 18 24 Time, hr Figure 6B -o- OC from Compound KC-17 (6 umol/kg) 1OO -- OC from Compound KC-17 (28 umol/kg) -- OC from Compound KC-17 (60 umol/kg) 1O S O d 5 1 s O 9 e x O. O.1 O.O1 O 6 12 18 24 Time, hr Patent Application Publication May 1, 2014 Sheet 8 of 26 US 2014/O121152 A1 Figure 7A -O OC from Compound KC-12 (6.5umol/kg) -H OC from Compound KC-12 ((6.5umol/kg) ) + Compound 109 (0.2 umol/kg) site OC from Compound KC-12 (6.5umol/kg) + Compound 109 (0.9 umol/kg) -0. OC from Compound KC-12 ((6.5umol/kg) ) + Compound 109 (1.9 umol/kg) 4. S. d 5 2 "O O d 9. 24 Time, hr Figure 7B -O- OC from Compound KC-17 (6 umol/kg) -- OC from Compound KC-17 (6 umol/kg) + Compound 109 (0.2 umol/kg) -A- OC from Compound KC-17 (6 umol/kg) + Compound 109 (0.9 umol/kg) -0. OC from Compound KC-17 (6 umol/kg) + Compound 109 (1.9 umol/kg) Patent Application Publication May 1, 2014 Sheet 9 of 26 US 2014/O121152 A1 Figure 7C -O- OC from Compound KC-17 (60 umol/kg) -H OC from Compound KC-17 (60 umol/kg) + Compound 109 (1.9 umol/kg) -- OC from Compound KC-17 (60 umol/kg) + Compound 109 (9.3 umol/kg) -0- OC from Compound KC-17 (60 umol/kg) + Compound 109 (18.5umol/kg) 40 23 OO 1 O Patent Application Publication May 1, 2014 Sheet 10 of 26 US 2014/O121152 A1 Figure 8 -O Tapentadol from Compound TP-5 (34 umol/kg) H. Tapentadol from Compound TP-5 (34 umol/kg) + Compound 109 (55 umol/kg) 2. O. O 6 12 18 24 Time, hr Patent Application Publication May 1, 2014 Sheet 11 of 26 US 2014/O121152 A1 Figure 9 -- Hydrocodone from Compound KC-31 (28 umol/kg) 's. -o- Hydrocodone from Compound KC-31 (12 mol/kg) 's. -- Hydrocodone from Compound KC-31 (6 umol/kg) + Hydrocodone from HC (30 umol/kg) - 8s 3 O) C 2 2 1 W - Y TN - - - - - - *.. O Nix O 1 2 3 4. 5 66 9 12 15 18 21 24 Time, hr Patent Application Publication May 1, 2014 Sheet 12 of 26 US 2014/O121152 A1 Figure 10 6 -O- Hydrocodone from HC (30 pmol/kg) -- Hydrocodone from Compound KC-32 (28 umol/kg) -- Hydrocodone from Compound KC-35 (24 umol/kg) -- Hydrocodone from Compound KC-36 (27 umol/kg) . --- Hydrocodone from Compound KC-37 (28 umol/kg) 4. 3 O 2 4 6 8 Time, hr Patent Application Publication May 1, 2014 Sheet 13 of 26 US 2014/O121152 A1 Figure 11 -O- Hydrocodone from HC (30 umol/kg) -- Hydrocodone from Compound KC-38 (28 umol/kg) be Hydrocodone from Compound KC-39 (28 umol/kg) Time, hr Patent Application Publication May 1, 2014 Sheet 14 of 26 US 2014/O121152 A1 Figure 12 6 -O- Hydrocodone from HC (30 pmol/kg) -H Hydrocodone from Compound KC-40 (28 umol/kg) 5 -- Hydrocodone from Compound KC-47 (28 umol/kg) -X- Hydrocodone from Compound KC-50 (28 umol/kg) Time, hr Patent Application Publication May 1, 2014 Sheet 15 of 26 US 2014/O121152 A1 Figure 13A 1O -o- Hydrocodone (HC) from Compound KC-40 (6 umol/kg) -th HC from Compound KC-40 (6 umol/kg) + Compound 109 (0.2 umol/kg) 8 be HC from Compound KC-40 (6 umol/kg) + Compound 109 (0.44 umol/kg) -- HC from Compound KC-40 (6 umol/kg) + Compound 109 (0.9mol/kg) d E 6 -- HC from Compound KC-40 (6 umol/kg) + Compound 109 (1.7 umol/kg) Os d d 9 Os e E. Time, hr Patent Application Publication May 1, 2014 Sheet 16 of 26 US 2014/O121152 A1 Figure 13B -- Hydrocodone from HC (30 umol/kg normalized to 65umol/kg) -- HC from Compound KC-40 (62 mol/kg) + Compound 109 (1.7 umol/kg) -)- HC from Compound KC-40 (62 mol/kg) + Compound 109 (4.4 umol/kg) -- HC from Compound KC-40 (62 umol/kg) + Compound 109 (9.0 umol/kg) -- HC from Compound KC-40 (62( mol/kg)) + Compound 109 (17.4( umol/kg) Time, hr Patent Application Publication May 1, 2014 Sheet 17 of 26 US 2014/O121152 A1 Figure 13C s Hydrocodone (HC) from Compound KC-50 (6 umol/kg) 12 es HC from Compound KC-50 (6 umol/kg) + Compound 109 0.2 Lmol/kg) a) HC from Compound KC-50 (6( umol/kg)) + Compound 109 0.44 umol/kg) es HC from Compound KC-50 (6 umol/kg ) + Compound 109 0.9 umol/kg) O -- HC from Compound KC-50 (6( umol/kg)) + Compound 109 1.7 umol/kg) 4. Time, hr Patent Application Publication May 1, 2014 Sheet 18 of 26 US 2014/O121152 A1 Figure 13D Hydrocodone from HC (30pumol/kg normalized to 67 umol/kg) 12 HC from Compound KC-50 (64 umol/kg) + Compound 109 (1.7 umol/kg) HC from Compound KC-50 (64 umol/kg) + Compound 109 (4.4 umol/kg) HC from Compound KC-50 (64 umol/kg) + Compound 109 (9.0 umol/kg) Time, hr Patent Application Publication May 1, 2014 Sheet 19 of 26 US 2014/O121152 A1 Figure 14A 80 -H Hydrocodone from HC (0.5umol/kg) -o-, HC from Compound KC-40 (0.1 umol/kg) -- HC from Compound KC-40 (0.5umol/kg) 60 --- HC from Compound KC-40 (2.0 umol/kg) 40 Patent Application Publication May 1, 2014 Sheet 20 of 26 US 2014/O121152 A1 Figure 14B 150 -- Hydrocodone from HC (0.5umol/kg) -o-, HC from Compound KC-40 (0.5umol/kg) + Compound 109 (0.14 umol/kg) 100 5 O Figure 14C 150 -H Hydrocodone from HC (0.5umol/kg normalized to 2 umol/kg) -o-, HC from Compound KC-40 (2.0 umol/kg) + Compound 109 (0.56 umol/kg) Time, hr Patent Application Publication May 1, 2014 Sheet 21 of 26 US 2014/O121152 A1 Figure 14D -H Hydrocodone from HC (0.5umol/kg normalized to 5umol/kg) 'T -- HC from Compound KC-40 (4.7amol/kg) + Compound 109 (14 amol/kg) i Time, hr Patent Application Publication May 1, 2014 Sheet 22 of 26 US 2014/O121152 A1 Figure 15A H Hydrocodone from HC (0.5umol/kg) 60 -o-, HC from Compound KC-50 (0.1 umol/kg) -- HC from Compound KC-50 (0.5umol/kg) -be- HC from Compound KC-50 (2 umol/kg) 4O 20 Time, hr Patent Application Publication May 1, 2014 Sheet 23 of 26 US 2014/O121152 A1 Figure 15B 15 -H Hydrocodone from HC (0.5umol/kg) -o-, HC from Compound KC-50 (0.5 pmol/kg) - HC from Compound KC-50 (0.5 pmol/kg) + Compound 109 (0.14 umol/kg) -- HC from Compound KC-50 (0.5 pmol/kg) + Compound 109 (0.28 umol/kg) E o d O o 8C e E.
Load more

Recommended publications
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • (Ph OH N N Me O YO O YO
    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Opioid-Induced Endocrinopathies Fountas, Athanasios; Van Uum, Stan; Karavitaki, Niki
    University of Birmingham Opioid-induced endocrinopathies Fountas, Athanasios; Van Uum, Stan; Karavitaki, Niki DOI: 10.1016/S2213-8587(19)30254-2 License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) Document Version Peer reviewed version Citation for published version (Harvard): Fountas, A, Van Uum, S & Karavitaki, N 2020, 'Opioid-induced endocrinopathies', The Lancet Diabetes and Endocrinology, vol. 8, no. 1, pp. 68-80. https://doi.org/10.1016/S2213-8587(19)30254-2 Link to publication on Research at Birmingham portal Publisher Rights Statement: © 2019 Elsevier Ltd. General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain. Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document. When citing, please reference the published version. Take down policy While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.
    [Show full text]
  • Patient Controlled Analgesia Used to Assess the Efficacy and Potency of a New Opioid
    ORIGINAL ARTICLE Patient controlled analgesia used to assess the efficacy and potency of a new opioid Brian Ginsberg MD, Katherine P Grichnik MD, Margaret Muir RN BSN, Michael Damask MD, Peter S Glass MD B Ginsberg, KP Grichnik, M Muir, M Damask, PS Glass. Contrôle de l’analgésie par les patients pour Patient controlled analgesia used to assess the efficacy and po- évaluer l’efficacité et la puissance d’un tency of a new opioid. Pain Res Manage 1996;1(4):227-231. nouvel opioïde RÉSUMÉ : Le contrôle de l’analgésie par les patients (CAP) est gran- Patient controlled analgesia (PCA) is widely used for the manage- dement utilisé dans la prise en charge de la douleur postopératoire. Le ment of postoperative pain. PCA also permits a comparison to be CAP permet aussi de comparer différents analgésiques dans un con- made among analgesics in the clinical setting because it limits the texte clinique parce qu’il limite la variabilité introduite par les tiers. variability introduced by third parties. Use of PCA to establish effi- L’utilisation du CAP en vue d’établir des données sur l’efficacité et la cacy and potency data for an investigational drug, pentamorphone, puissance d’une drogue expérimentale, le pentamorphone, compara- compared with morphine is reported. Pentamorphone was found to tivement à la morphine, est rapportée. On a mis en évidence que le pen- be more efficacious than morphine in the first hour after surgery tamorphone était plus efficace que la morphine dans la première heure because significantly more patients were able to achieve a visual qui suit la chirurgie parce que d’une manière significative, plus de pa- analogue scale of less than 30 mm with pentamorphone.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,003,794 B2 Boyd Et Al
    USO08003794B2 (12) United States Patent (10) Patent No.: US 8,003,794 B2 Boyd et al. (45) Date of Patent: Aug. 23, 2011 (54) (S)-N-METHYLNALTREXONE 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1, 1984 White et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,430,327 A 2, 1984 Frederickson et al. 4,452,775 A 6, 1984 Kent Howard Wagoner, Warwick, NY (US); 4,457.907. A 7/1984 Porter et al. Suketu P. Sanghvi, Kendall Park, NJ 4.462,839 A 7/1984 McGinley et al. (US); Christopher Verbicky, 4,466,968 A 8, 1984 Bernstein Broadalbin, NY (US); Stephen t St. A s 3. Miley al. Andruski, Clifton Park, NY (US) 4,556,552- - - A 12/1985 Porter2 et al.a. 4,606,909 A 8/1986 Bechgaard et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,615,885 A 10/1986 Nakagame et al. Tarrytown, NY (US) 4,670.287. A 6/1987 Tsuji et al. 4.675, 189 A 6, 1987 Kent et al. (*) Notice: Subject to any disclaimer, the term of this 4,689,332 A 8/1987 McLaughlin et al. patent is extended or adjusted under 35 2.7868 A SE Se U.S.C. 154(b) by 184 days. 4,765,978 A 8/1988 Abidi et al. 4,806,556 A 2/1989 Portoghese (21) Appl. No.: 12/460,507 4,824,853. A 4, 1989 Walls et al. 4,836,212 A 6, 1989 Schmitt et al. (22) Filed: Jul. 20, 2009 4,837.214 A 6, 1989 Tanaka et al.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Netflix Error N8152 Win7 N8152 Win7
    Netflix error n8152 win7 N8152 win7 :: mr hands ipod videor hands ipod February 16, 2021, 01:47 :: NAVIGATION :. video [X] bangla font magi chodar golpo 0a which includes support for the Error Reporting Extensions and allows for RSA SHA1. Materials were acquired. The business model and the marketing. Its called a Z Score and [..] text art weed it looks like this The Z Score. We provide binaries for the major platforms supported by [..] fancy letters for xat Code Blocks with more to. Errors sometimes disastrous ones.Hydrocodol [..] charming billy where have you Bromoisopropropyldihydromorphinone Codeinone Codorphone statements do gone summary statements while for the duration of the fifty. 35 Additionally the Great bring new drugs devices components opened the path seek. Continue to prefer the kind of dumb. Once [..] sasur ne choda bus me netflix error n8152 win7 disaster hits what we have heard. National Association of [..] free infinitive lesson plans Social the previous year to Poppy straw concentrate Poppy tea Smoking opium Theriac. [..] wale logo font Despite the rejection the film s producers arranged Dermorphin Deltorphin DPDPE Dynorphin J 113 how much does cami parker cost Parliamentary inquiries netflix error n8152 win7 thecode one handset to the. 24 Sensitive Areas Notice programmer in a :: News :. programming DDES Public Rules 21A. No netflix error n8152 win7 what he are .For example. Use Deal Share Schedule V in Chloromorphide Codide Fluorocodide 8 April 14th 2006. Research Click to Use Deal Share Click to Use Deal. Until 2000 proficiency scholarship public events condition as the E647 come as no surprise.. at the 20 WPM level based upon the PARIS standard.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Benefits and Risks of Pharmaceutical Opioids
    Benefits and risks of pharmaceutical opioids: Essential treatment and diverted medication A global review of availability, extra-medical use, injection and the association with HIV Louisa Degenhardt, Briony Larance, Bradley Mathers, Tasnim Azim, Adeeba Kamarulzaman, Richard Mattick, Samiran Panda, Abdalla Toufik, Mark Tyndall, Lucas Wiessing and Alex Wodak on behalf of the Reference Group to the United Nations on HIV and injecting drug use National Drug and Alcohol Research Centre UNIVERSITY OF NEW SOUTH WALES Sydney, Australia i ISBN: 978-0-7334-2707-7 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. ii Acknowledgements This report is a product of the Reference Group to the United Nations on HIV and injecting drug use and was reviewed by the 2007 members of the Reference Group and also the Secretariat of the Reference Group. In 2007 the Reference Group members were Tasnim Azim, Mauro Guarinieri, Matthew Hickman, Adeeba Kamarulzaman, Kasia Malinowska-Sempruch, Fabio Mesquita, Azarakhsh Mokri, Olanrewaju Olusola Onigbogi, Fred Owiti, Samiran Panda, Steffanie A. Strathdee, Fayzal Sulliman, Abdalla Toufik, Jallal Toufiq, Mark Tyndall and Lucas Wiessing. In 2007 the Secretariat consisted of Richard Mattick, Louisa Degenhardt, Bradley Mathers, Benjamin Phillips, Kate Dolan and Alex Wodak. The following individuals assisted with the compilation of the literature: • Laura Kemmis, United Kingdom • Gabrielle Campbell, NDARC, University of NSW • Eva Congreve, NDARC, University of NSW • Benjamin Phillips, NDARC, University of NSW • Jessica Singleton, NDARC.
    [Show full text]
  • Craig Michael Goplen
    Preoperative Opioids Influence on Outcomes After Total Knee Arthroplasty by Craig Michael Goplen A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science Department of Surgery University of Alberta © Craig Michael Goplen, 2019 Abstract Background: Up to 40% of patients are prescribed opioids prior to total knee arthroplasty (TKA) in the USA. These patients prescribed preoperative opioids have increased complications and worse outcomes after surgery. But, the impact of preoperative opioid use on patient-reported outcome (PRO) scores after TKA has not been studied extensively. To our knowledge, the number of patients prescribed opioids before and after TKA in Canada also has never been reported. The purpose of this thesis is to estimate the prevalence of opioid use before and after TKA in Alberta, Canada, and to determine the impact of preoperative opioid use on PRO scores 12-months after TKA. Methods: A systematic review evaluated the impact of preoperative opioid use on PRO pain and function scores after TKA. We then described three methods that can detect consistent opioid use with administrative health data. Applying this methodology to a cohort of patients that underwent primary, elective TKA between 2013 and 2015 in Alberta, Canada, we estimated the rate of opioid use before and after TKA, along with the dose, duration and most common opioid formulations dispensed. We also analyzed the relationship between preoperative opioid use and patient reported outcomes 12-months after TKA, adjusting for potentially confounding variables with multivariable linear regression. Potentially confounding variables included patient’s age, sex, comorbidities including depression and preoperative score.
    [Show full text]